Evidência de interação entre a camomila (Matricaria recutita) e o 5-fluorouracil frente à atividade antineoplásica em camundongos com sarcoma 180

• Ano de defesa: 2018
• Autor(a) principal: Santos, Sara Albuquerque dos
• Orientador(a): Carvalho, Adriana Andrade
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Programa de Pós-Graduação: Pós-Graduação em Ciências Fisiológicas
• Palavras-chave em Português: Câncer; Interações medicamentosas; Plantas medicinais; Agentes antineoplásicos; Camomila; Antitumoral; Toxicidade; Matricaria recutita
• Palavras-chave em Inglês: Cancer; Toxicity; Drug interactions; Medicinal plants
• Área do conhecimento CNPq: CIENCIAS BIOLOGICAS::FISIOLOGIA
• Link de acesso: http://ri.ufs.br/jspui/handle/riufs/12599

Cancer is the most widespread cause of illness on the planet. It is understood as a set of more than 100 cellular diseases, caused by mutations and changes in mechanisms of epigenetic regulation. Popular knowledge provides a basis for the use of several plants with antitumor potential and many patients associate their use with the standard treatments for cancer, however, ignoring the existence of possible drug interactions or potentiation of adverse effects. Particularly infused Matricaria recutita has been popularly used in association with chemotherapy. This study aimed to evaluate the effect of the association between Matricaria recutita and the antineoplastic drug 5-fluorouracil in the treatment of mice transplanted with sarcoma 180. For this purpose, the aqueous extract of Matricaria recutita (EAMR) was prepared from the inflorescences, whose chromatographic record detected the presence of flavonoids such as luteonin, quecertin, rutin, and phenolic compounds such as caffeic acid. In vitro cytotoxicity of EAMR was evaluated against 5 human tumor cell lines: prostate (PC-3), colon (HCT-116), breast adenocarcinoma (MCF-7), acute promyelocytic leukemia (HL-60) and glioblastoma (SNB-19), and non-malignant fibroblast (L929) through the MTT assay. EAMR showed no cytotoxic activity in any of the cell lines tested, with IC 50> 50 μg / mL. For the in vivo experiment, swiss mice divided into experimental groups were treated with vehicle solution (CTRL-), 5-FU 25 mg / kg / day (CTRL +), EAMR 100, EAMR 200, EAMR 100 + 5-FU and EAMR 200 + 5-FU (mg / kg / day), n = 07 per group. The EAMR was administered v.o. and 5-FU i.p for 7 days of treatment. Tumor Inhibition (IT) and toxicological, biochemical, hematological and histopathological parameters were analyzed. Treatment of the associated groups EAMR 100 + 5-FU and EAMR 200 + 5-FU reduced tumor growth, with inhibition percentages of 66.1% and 87.7%, respectively, by probable (p <0.05) synergism between its compounds. In relation to the toxicological parameters, there was a reduction in body mass from the 3rd day of treatment in the associated groups (-1.2 ± 0.3 and -1.3 ± 0.3 g, respectively) (p <0.05) , demonstrating the potentiation of 5-FU in the loss of body mass, in addition to the presence of diarrhea, mainly for the higher dose. There was alteration of the heart mass in the associated groups 100 and 200 (0.50 ± 0.01 and 0.51 ± 0.02g, respectively) (p <0.05); (0.23 ± 0.02, 0.31 ± 0.03, and 0.21 ± 0.02 g, respectively) (p <0.05) 0.05) without potentiating the effect; and reduction of hepatic mass in the EAMR200 + 5-FU group, but without elevation of hepatic enzymes. There was no potentiation of myelosuppression (leucopenia and thrombocytopenia) in the associated groups. Histopathological analyzes of the tumors showed reduction of mitoses and presence of apoptotic areas in the associated groups, as well as reduction of the extent of the white pouch in the spleen. The results of this study suggest that the association between Matricaria recutita and 5-FU potentiates the antitumor activity in a synergistic way, intensifying some adverse effects.